Cargando…
SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023356/ https://www.ncbi.nlm.nih.gov/pubmed/35484041 http://dx.doi.org/10.1016/j.vaccine.2022.04.061 |
| _version_ | 1784690329277956096 |
|---|---|
| author | Antonopoulou, Tania Athanassakis, Irene |
| author_facet | Antonopoulou, Tania Athanassakis, Irene |
| author_sort | Antonopoulou, Tania |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9023356 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90233562022-04-22 SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination? Antonopoulou, Tania Athanassakis, Irene Vaccine Commentary Elsevier Ltd. 2022-05-20 2022-04-22 /pmc/articles/PMC9023356/ /pubmed/35484041 http://dx.doi.org/10.1016/j.vaccine.2022.04.061 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Commentary Antonopoulou, Tania Athanassakis, Irene SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination? |
| title | SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination? |
| title_full | SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination? |
| title_fullStr | SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination? |
| title_full_unstemmed | SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination? |
| title_short | SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination? |
| title_sort | sars-cov-2 immunogenicity: is s protein the best target for vaccination? |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023356/ https://www.ncbi.nlm.nih.gov/pubmed/35484041 http://dx.doi.org/10.1016/j.vaccine.2022.04.061 |
| work_keys_str_mv | AT antonopouloutania sarscov2immunogenicityissproteinthebesttargetforvaccination AT athanassakisirene sarscov2immunogenicityissproteinthebesttargetforvaccination |